Biocryst Pharmaceuticals Inc Stock Price, News & Analysis

BioCryst Pharmaceuticals (Nasdaq: BCRX) has appointed Babar Ghias as Chief Financial Officer and Head of Corporate Development. Ghias joins from AvenCell Therapeutics, where he served as CFO since 2022, bringing significant experience in deal-making and operations in rare disease companies.

Throughout his career, Ghias has raised over $1 billion in capital and completed over $80 billion in transactions as an investment banker at Credit Suisse. His previous roles include executive positions at Paragon Biosciences, where he launched four biotechnology companies, and CFO at Marathon Pharmaceuticals, where he led the company's successful sale.

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced the granting of restricted stock units (RSUs) to eight newly-hired employees. The compensation committee approved a total of 57,000 shares of BioCryst common stock as inducement awards on July 1, 2025.

The RSUs will vest over four years in equal annual installments, starting from the one-year anniversary of the grant date, contingent on continued employment. These grants were made under Nasdaq Listing Rule 5635(c)(4) and are subject to BioCryst's Inducement Equity Incentive Plan terms.

BioCryst Pharmaceuticals (Nasdaq: BCRX) has agreed to sell its European ORLADEYO® business to Neopharmed Gentili for up to $264 million, comprising a $250 million upfront payment and up to $14 million in future milestones.

The company plans to use the proceeds to retire its remaining $249 million term debt from Pharmakon, eliminating approximately $70 million in future interest payments. BioCryst expects to end 2027 with approximately $700 million in cash and no term debt, representing a $400 million increase from prior guidance.

The transaction, expected to close by early October, includes the transfer of BioCryst's European organization to Neopharmed Gentili, resulting in projected annual operating expense savings of at least $50 million for BioCryst.

BioCryst Pharmaceuticals presented new data demonstrating the long-term efficacy and safety of ORLADEYO (berotralstat) for hereditary angioedema (HAE) treatment across all age groups at EAACI 2025. Key findings from four studies showed: (1) In pediatric patients, an 86% reduction in attacks requiring professional care was observed after 12 weeks of treatment. (2) The Berolife study showed sustained attack reduction in patients aged >12 years, with median monthly attacks decreasing from 1.0 to 0.44 after six months. (3) Quality of life studies revealed significant improvements in patient outcomes, with 60% achieving Minimal Clinically Important Difference at week 24. (4) Focus group results indicated positive patient experiences, including better disease control and easier treatment management compared to previous therapies. The drug demonstrated consistent safety across all studies, with common side effects including nasopharyngitis and headache.

BioCryst Pharmaceuticals (BCRX) has received approval from Colombia's National Institute of Drug and Food Surveillance (INVIMA) for ORLADEYO (berotralstat), an oral, once-daily treatment for hereditary angioedema (HAE) attack prevention in patients aged 12 and older. This approval expands ORLADEYO's presence in the pan-Latin America region, where it's already approved in Chile, Argentina, Brazil, Mexico, and Peru. BioCryst's partnership with Pint Pharma GmbH involves exclusive collaboration for registration and promotion in the region, with Pint handling marketing authorizations and commercialization responsibilities.

BioCryst Pharmaceuticals announced that ORLADEYO (berotralstat) has received reimbursement approval in the Netherlands for preventing hereditary angioedema (HAE) attacks in patients 12 years and older. This milestone completes ORLADEYO's reimbursement coverage across all major European countries, marking significant progress for the first oral, once-daily preventive therapy for HAE. The approval follows a positive recommendation from Zorginstituut Nederland and builds upon the European Commission's marketing authorization granted in April 2021. ORLADEYO is now commercially available in over 30 countries, representing a major advancement in HAE treatment accessibility.

BioCryst Pharmaceuticals (BCRX) has granted restricted stock units (RSUs) to seven newly-hired employees as employment inducements. The compensation committee approved RSUs covering 47,250 shares of BioCryst common stock, effective June 2, 2025. These equity awards, granted under Nasdaq Listing Rule 5635(c)(4), will vest over four years in equal annual installments, starting from the one-year anniversary of the grant date. The vesting is contingent upon continued employment with BioCryst. The RSUs are governed by BioCryst's Inducement Equity Incentive Plan and individual RSU agreements.

BioCryst Pharmaceuticals (BCRX) announced it will present new data on ORLADEYO (berotralstat), its oral once-daily treatment for hereditary angioedema (HAE), at the 2025 EAACI meeting in Glasgow. The company will showcase four abstracts highlighting different aspects of ORLADEYO's effectiveness: a pooled analysis of quality of life data from APeX-2 and APeX-J trials, patient perceptions from focus groups, long-term prophylaxis findings from the Berolife study, and interim results from APeX-P showing reduced HAE attacks in pediatric patients. The presentations are scheduled for June 14-15, 2025.

BioCryst Pharmaceuticals presented new data at the 14th C1-inhibitor Deficiency & Angioedema Workshop demonstrating ORLADEYO's (berotralstat) effectiveness in reducing hereditary angioedema (HAE) attacks across all age groups. The APeX-P trial showed significant symptom reduction in young children, with angioedema symptoms decreasing from 11% to 4% over 12 weeks. The Italian expanded access program revealed improved disease control and quality of life scores, while the Berolife study demonstrated sustained attack rate reduction in adolescents from 1.8 to 0.55 attacks per month. The drug showed consistent safety profiles across all age groups, with common side effects including nasopharyngitis, upper respiratory tract infection, and headache. The data supports ORLADEYO as an effective oral, once-daily prophylactic treatment option for HAE patients of all ages.